Intellia Therapeutics Stock Forecast

Stock Price Forecast

According to 23 analysts polled by S&P Global, Intellia Therapeutics stock has a consensus rating of "Buy" and an average price target of $26.63. The average 1-year stock price forecast is 111.35% higher than the current stock price, while the lowest is $8.00 (-36.51%) and the highest is $95 (+653.97%).

Price Target: $26.63 (+111.35%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$8.00	$26.63	$19	$95
Change	-36.51%	+111.35%	+50.79%	+653.97%

Analyst Ratings

The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	7	7	7	8	8	8
Buy	4	2	2	4	4	4
Hold	10	8	8	7	9	8
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	1	1
Total	22	18	18	20	23	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
William Pickering Bernstein	Bernstein	Hold Maintains $13 → $17	Hold	Maintains	$13 → $17	+34.92%	May 13, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $30 → $25	Strong Buy	Maintains	$30 → $25	+98.41%	May 13, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $58 → $49	Strong Buy	Maintains	$58 → $49	+288.89%	May 12, 2026
David Nierengarten Wedbush	Wedbush	Hold Reiterates $12	Hold	Reiterates	$12	-4.76%	May 12, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $48 → $58	Strong Buy	Maintains	$48 → $58	+360.32%	Apr 28, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

61.27M

from 67.67M

-9.46%

from 67.67M

Revenue Next Year

119.14M

from 61.27M

94.46%

from 61.27M

EPS This Year

-3.31

from -3.81

EPS Next Year

-2.79

from -3.31

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	33.05M	52.12M	36.28M	57.88M	67.67M	61.27M	119.14M
Revenue Growth	-43.01%	57.69%	-30.40%	59.55%	16.92%	-9.46%	94.46%
EPS	-3.78	-6.16	-5.42	-5.25	-3.81	-3.31	-2.79
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	24	23

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	81.7M	231.6M
Avg	61.3M	119.1M
Low	35.3M	47.8M

Revenue Growth

Revenue Growth	2026	2027
High	20.8%	278.1%
Avg	-9.5%	94.5%
Low	-47.9%	-22.0%

EPS Forecast

EPS	2026	2027
High	-2.04	-2.27
Avg	-3.31	-2.79
Low	-3.75	-3.92

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.